Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
2.685
-0.045 (-1.65%)
Jul 11, 2025, 11:50 AM - Market open
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $1.56M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $1.86M, up 572.56% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$1.86M
Revenue Growth
+572.56%
P/S Ratio
241.08
Revenue / Employee
$34,500
Employees
54
Market Cap
569.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATAI News
- 8 days ago - Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD - Seeking Alpha
- 10 days ago - Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data - Benzinga
- 10 days ago - atai Life Sciences Announces $50 Million Private Placement Financing - GlobeNewsWire
- 10 days ago - atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewsWire
- 5 weeks ago - atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - GlobeNewsWire
- 6 weeks ago - atai Life Sciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - GlobeNewsWire
- 2 months ago - atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire